Broadly reactive anti-VHH antibodies for characterizing, blocking, or activating nanobody-based CAR-T cells.

ABSTRACT:

Background

Production of chimeric antigen receptor T cell (CAR-T) therapies depends on antibody reagents to label, isolate, and expand T cell products. We sought to create antibody tools specific for the variable domain of heavy-chain only antibodies (VHHs), also known as nanobodies, used in some CARs.

Methods

We immunized a mouse with VHH and selected two murine monoclonal antibodies (mAbs) that bind to distinct epitopes in conserved framework regions of llama-derived VHHs, and not to human VH domains. Anti-VHH mAbs were characterized by enzyme-linked immunosorbent assay, surface plasmon resonance, and hydrogen-deuterium exchange mass spectrometry; were then tested for cell/tissue labeling and for modulating cellular activity in VHH-CAR-T cells.

Results

We produced a

SUBMITTER: McComb S 

PROVIDER: S-EPMC12451263 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature